Estimated reading time: 4 minutes
For decades, the standard answer to ‘Can lupus be cured?’ has been a firm no. Lupus is managed, not cured. It is quieted, not eliminated.
That answer may be changing.
CAR-T cell therapy is a form of treatment that genetically engineers your own immune cells, and it has shown extraordinary early results in lupus clinical trials. In some of those trials, the word ‘cure’ is being used cautiously but genuinely.
“CAR-T cell therapy — very exciting. It’s been used for several autoimmune diseases to the point that they’re saying that they have cured. Remember, I said there’s no cure for autoimmune diseases — but they are saying that these experimental trials and clinical trials have been able to cure certain cancers and certain autoimmune diseases.”
Dr. Shazia Beg, UCF Health & UCF College of Medicine
Table of contents
What Is CAR-T Cell Therapy?
CAR-T stands for Chimeric Antigen Receptor T-cell therapy. Specifically, it is a form of highly personalized medicine that uses your own immune cells (specifically your T-cells) as the treatment vehicle.
T-cells are the front-line soldiers of your immune system. In lupus, they play a central role in the misdirected immune attack on the body’s own tissues. CAR-T therapy works by intercepting those T-cells, reprogramming them in a laboratory, and sending them back into the body better equipped to target the cells responsible for the disease.
How Does the Process Work? A Step-by-Step Explanation
Step 1
A clinical provider collects your T-cells from your blood through a standard blood draw.
Step 2
We send the cells to a specialized laboratory, where scientists genetically modify them — reprogramming them to better recognize and attack the immune cells driving lupus.
Step 3
The laboratory grows the modified T-cells into hundreds of millions of copies.
Step 4
Your care team infuses those modified T-cells back into your body, where they go to work targeting the source of the disease.
“What they do is — first they collect your T-cells from your blood, then they take it to the lab and they genetically modify your T-cells. It has to be that one particular patient’s T-cells — taken out, modified, and put back. And now these T-cells are much more effective. They are able to target the lupus portion of the problem much, much better.”
Dr. Shazia Beg, UCF Health & UCF College of Medicine
What Do the Early Results Show?
The results from early clinical trials have genuinely surprised researchers — and given the rheumatology community reason for real optimism.
“They say 90% of patients in early clinical trials have achieved remission — which is amazing.”
Dr. Shazia Beg, UCF Health & UCF College of Medicine
A 90% remission rate in any chronic disease would be remarkable. In a condition as complex as lupus — where patients present with different organ involvement, different severity levels, and varied responses to treatment — it is extraordinary.
It is important to be precise: these are early clinical trial results, and long-term durability studies are still ongoing. But some trial participants have sustained remission with no ongoing medications, a milestone that conventional lupus therapies rarely, if ever, achieve.
What Are the Risks and Limitations?
The process requires hospital admission and a preparatory course of chemotherapy before your care team infuses the modified T-cells.
CAR-T cell therapy is not a pill you take at home. It is an intensive, hospital-based procedure that carries real risks that must be weighed carefully against potential benefits.
The process requires hospital admission and a preparatory course of chemotherapy before the modified T-cells are infused. For example, known side effects include:
- Neurological symptoms (cytokine release syndrome)
- High fever and blood pressure changes
- Elevated risk of infection
- Prolonged monitoring period after infusion
“It’s not for everybody. It’s not like giving you a pill and you just take it at home. You have to be admitted to the hospital. There’s a lot of things that can happen. But overall, they say most patients tolerated it pretty well.”
Dr. Shazia Beg, UCF Health & UCF College of Medicine
Researchers still consider CAR-T therapy for lupus experimental. Medical centers do not yet offer it broadly outside of clinical trials, and it is not FDA-approved as a standard lupus treatment. Patients who have not responded adequately to conventional therapies typically make the most appropriate candidates for trial consideration.
Are There Clinical Trials Open in Florida Right Now?
Yes — and this is particularly relevant for patients in Central Florida.
“There are places in Central Florida, in Tampa, in Miami that have clinical trials for CAR-T cells. It depends on what the patient has, what they’ve tried, if they meet criteria to get this treatment.”
Dr. Shazia Beg, UCF Health & UCF College of Medicine
For lupus patients in the UCF Health region who have struggled to achieve disease control through conventional therapies, this means potential access to one of the most advanced investigational treatments in autoimmune medicine — within the state.
Speaking with your rheumatologist is the first step to understanding whether you may meet eligibility criteria for any of these trials.
What Else Is Coming in the Lupus Treatment Pipeline?
CAR-T is not the only promising development on the horizon. Dr. Beg highlighted several additional investigational therapies in active development:
- New B-cell targeting agents that build on and expand existing biologic approaches
- Dual-pathway drugs that target two parts of the immune system simultaneously — providing more comprehensive disease suppression
- Small-molecule oral medications, similar to drugs already approved for rheumatoid arthritis, being tested for lupus
- Precision medicine platforms that match specific drugs to a patient’s individual biomarkers and genetics — aiming to predict which treatment will work best before prescribing
The Bottom Line
CAR-T cell therapy for lupus is still experimental, but the early data is unlike anything the rheumatology field has seen in modern memory. For patients living with difficult-to-control lupus, it represents a genuinely new category of possibility.
These treatments are still experimental and still being studied. But they are in the horizon — and they are getting closer.
About Dr. Shazia Beg
Dr. Shazia Beg is a board-certified rheumatologist and founding faculty member at UCF College of Medicine, where she has practiced since 2011. She serves as Program Director of the UCF Rheumatology Fellowship Program and Medical Director of UCF Health. She specializes in lupus and autoimmune diseases and sees patients at UCF Health in Lake Nona and East Orlando, Florida.
- English
- Hindi
- Urdu
Post Tags
- CCAR-T Cell Therapy Clinical Trials immunotherapy Medical Breakthroughs rheumatology